Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic solid tumor for which there is no curative treatment * No known brain metastases * Performance status - ECOG 0-2 * Performance status - Karnofsky 60-100% * WBC at least 3,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin normal * AST/ALT no greater than 2.5 times upper limit of normal (ULN) * Creatinine no greater than ULN * Left ventricular function at least lower limit of normal if received prior doxorubicin * No grade II or IV tilt-table test * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * No thrombotic event within the past 6 months * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No prior allergic reaction to compounds of similar chemical or biological composition to study drugs * No other concurrent uncontrolled illness * No ongoing or active infection * No psychiatric illness or social situation that would preclude study compliance * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) * Prior paclitaxel allowed * At least 2 weeks since prior hormonal therapy * No concurrent steroids or hormonal therapy except steroids to prevent hypersensitivity reactions to paclitaxel or hormonal therapy for non-disease-related conditions (e.g., insulin for diabetes) * At least 4 weeks since prior radiotherapy * At least 4 weeks since prior surgery * Recovered from prior therapy * No other concurrent investigational agents * No concurrent combination anti-retroviral therapy for HIV-positive patients * No concurrent anticoagulation therapy * Concurrent pamidronate or zoledronate allowed for treatment of hypercalcemia or for palliation of skeletal metastases